Lactate and choline metabolites detected in vitro by nuclear magnetic resonance spectroscopy are potential metabolic biomarkers for PI3K inhibition in pediatric glioblastoma.
about
Pharmacodynamic Biomarker Development for PI3K Pathway TherapeuticsImaging Extracellular Lactate In Vitro and In Vivo Using CEST MRI and a Paramagnetic Shift Reagent.Inhibition of Pediatric Glioblastoma Tumor Growth by the Anti-Cancer Agent OKN-007 in Orthotopic Mouse Xenografts.Alterations in cellular metabolome after pharmacological inhibition of Notch in glioblastoma cells.In Situ Characterizing Membrane Lipid Phenotype of Human Lung Cancer Cell Lines Using Mass Spectrometry ProfilingMR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy.Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.Validating a robust double-quantum-filtered (1) H MRS lactate measurement method in high-grade brain tumoursProbing the PI3K/Akt/mTor pathway using (31)P-NMR spectroscopy: routes to glycogen synthase kinase 3.MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy.Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas.
P2860
Q26766292-C5BF3681-6E6F-43DE-AF01-4F09D6D78636Q31149687-BB2A4133-4E3D-4A9F-8061-C5CEE654BC29Q35738941-13D40ABD-224A-4C76-BEFA-52AD45DF779DQ36633528-E210CF95-BA92-4A77-B46F-A412837B0C57Q36882566-2FE6CC38-A25D-4C4D-A6B0-814818689FA5Q36918102-B1AE0135-F756-4CBD-ACD0-B43301BEF261Q37660266-78ED43F6-7B6A-4810-A319-8F84DFCA87BDQ38554422-026C3031-6B37-40AB-ABD0-11482F14E901Q38680891-05914B10-ED8A-4914-B74A-E619D9088068Q38720885-89563E9C-A3B1-4DB0-A854-5C9D5F0CDA14Q38840489-B39C45AA-36F0-4818-AF8D-56ADF2056A18Q39499557-16FF64EA-8F66-47DE-B073-94079464606DQ42120404-2F0CB22D-A231-41F8-B3FA-08D57EAE11DFQ43296499-9121F8F8-D4AC-4643-9DFD-570EEDC79189Q55261716-93A825EC-A84B-417A-B367-A04A0E57A93F
P2860
Lactate and choline metabolites detected in vitro by nuclear magnetic resonance spectroscopy are potential metabolic biomarkers for PI3K inhibition in pediatric glioblastoma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Lactate and choline metabolite ...... ion in pediatric glioblastoma.
@en
type
label
Lactate and choline metabolite ...... ion in pediatric glioblastoma.
@en
prefLabel
Lactate and choline metabolite ...... ion in pediatric glioblastoma.
@en
P2093
P2860
P50
P1433
P1476
Lactate and choline metabolite ...... ion in pediatric glioblastoma.
@en
P2093
Alice Agliano
Andrew D J Pearson
Geetha Balarajah
L Elizabeth Jackson
Lynley V Marshall
Nada M S Al-Saffar
P2860
P304
P356
10.1371/JOURNAL.PONE.0103835
P407
P577
2014-08-01T00:00:00Z